Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours
ConclusionsEzabenlimab was well tolerated and associated with durable antitumour activity in multiple solid tumours, comparable to other immune checkpoint inhibitors in similar patient populations and treatment settings.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Anemia | Canada Health | Cancer | Cancer & Oncology | Immunotherapy | Japan Health | Netherlands Health | Study | Toxicology | UK Health | USA Health